Search Results
10
Everything
Search Filters
Organization
Senti Biosciences, Inc.
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
March 20, 2025 16:01 ET
|
Senti Biosciences, Inc.
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – –...
Senti Bio Appoints Feng Hsiung to Board of Directors
March 13, 2025 16:01 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a clinical-stage biotechnology company developing...
Senti Bio Strengthens Leadership Team with Strategic Hires
February 25, 2025 08:00 ET
|
Senti Biosciences, Inc.
– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO,...
Senti Bio Announces Additional $11.5 Million of Financing
January 06, 2025 09:00 ET
|
Senti Biosciences, Inc.
– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced in June 2024 – – Cash runway guidance extended into 2026 – ...
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
December 16, 2024 08:00 ET
|
Senti Biosciences, Inc.
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) – SOUTH SAN...
Senti Biosciences Announces New Employment Inducement Grants
December 03, 2024 20:00 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
December 02, 2024 07:10 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing...
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML
December 02, 2024 07:02 ET
|
Senti Biosciences, Inc.
– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – – Dose escalation is continuing with...
Senti Bio Appoints Fran Schulz to Board of Directors
December 02, 2024 07:00 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing...
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
November 14, 2024 16:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene...